Weight-Loss Drugs Help Hearts

Originally developed to manage type 2 diabetes, drugs like Ozempic and Wegovy are a class of medications known as GLP-1 receptor agonists. They work by mimicking a gut hormone that regulates blood sugar and appetite, which led to their widespread use for weight management. Initial theories suggested the cardiovascular benefits were a byproduct of weight loss. However, the landmark SELECT trial, a large-scale international study, found that semaglutide (the active ingredient) reduced the risk of major adverse cardiovascular events by 20% in overweight or obese patients with pre-existing heart disease, regardless of how much weight they lost. This suggests the drugs have a direct protective effect on the cardiovascular system. Proposed mechanisms include reducing inflammation, improving blood vessel function, lowering blood pressure, and having direct effects on the heart muscle. The newest research, conducted on animal models, delves deeper into post-heart attack scenarios. A study led by the University of Bristol and University College London found these drugs can prevent a complication called "no-reflow," where tiny blood vessels in the heart remain constricted even after the main artery is cleared. This complication affects up to half of all heart attack patients and increases the risk of death or heart failure. The study suggests the drugs work by relaxing specific cells called pericytes that wrap around small blood vessels, allowing blood flow to be restored to the damaged heart tissue. This finding has led researchers to propose that paramedics could one day administer these drugs at the scene of a heart attack. While showing significant promise, these medications are not without drawbacks. Common side effects are gastrointestinal and can include nausea, vomiting, and diarrhea. The high cost is also a significant barrier, with monthly out-of-pocket expenses potentially exceeding $1,000.